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Abstract
Background: To report the clinical outcome after a Single Shot 3D-CRT PBI (SSPBI) in breast cancer patients after
conservative surgery (ClinicalTrials.gov Identifier: NCT01316328).
Methods: A dose of 18Gy (in the first 4 patients) and 21Gy (in the remaining 60 patients) was prescribed in a
single session and delivered to the index area (i.e. the area of breast including the primary tumor bed and the
surrounding tissue) using 3D-CRT with patients in prone position. Acute and late toxicity was assessed using the
National Cancer Institute’s CTC for Adverse Events. Cosmesis was defined based on modified Harvard criteria.
Differences between dosimetric or clinical parameters of patients with/without G2 or more late toxicity or
unsatisfactory (poor or fair) cosmetic outcome were evaluated with the Mann-Whitney test. Odds ratios and 95%
confidence interval were calculated for cosmesis and fibrosis. Univariate and multivariate analyses(UVA/MVA) were
used to determine covariates associated with an increase in fibrosis or fat necrosis rate.
Results: Sixty four patients were enrolled. With a median follow-up of 3 years, G2 and G3 subcutaneous fibrosis
was detected in 20(31%) and in 8(13%) patients, and ≥G2 fat necrosis was observed in 2(3%) patients. Good to
excellent, fair and poor cosmesis was observed in 38(59%), 23(36%) and 3(5%) patients, respectively. Based on UVA,
the breast volume receiving more than 21Gy (V21Gy) was found to be a predictor of the ≥G1 or ≥G2 fibrosis/fat
necrosis. Based on MVA, V21Gy was confirmed as a predictor for ≥G1 fibrosis/fat necrosis, the results correlated as a
trend for ≥G2. Cosmesis was correlated with whole breast (WB) mean dose (p = 0.030).
Conclusion: Our choice of a single dose of 21Gy significantly increased the treatment related toxicity. However,
this should not discourage novel SSPBI approaches with lower equivalent doses.
Background
A number of studies [1-3] have reported that most
(81%-100%) intra breast tumor recurrences after breast
conserving therapy occur in close proximity to the
tumor bed, thus providing the rationale for an adjuvant
radiotherapy limited to the Index Area, i.e. the area of
breast including the primary tumor bed and the sur-
rounding tissue.
In fact, the risk of recurrence outside the operative
area has been reported to be similar to the risk of new
primary cancer in the contra-lateral breast, usually not
irradiated [4]. This new philosophy of Partial Breast
Irradiation(PBI) has suggested new clinical and technical
radio-therapeutic approaches. It has been theorized that,
limiting the dose to smaller volumes, larger radiation
fractions can safely be used reducing the overall treat-
ment time.
Thus, Accelerated PBI (APBI) has been promoted in
phase I-III trials [5-9] designed to test the feasibility and
equivalence compared with standard Whole Breast Irra-
diation(WBI) in properly selected low-risk early breast
cancer patients after breast conserving surgery(BCS).
A number of approaches are now available for the
implementation of APBI including: intra-operative
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rays[10], multi-catheter interstitial brachytherapy [11],
balloon-based high dose rate (HDR) brachytherapy [12],
P d - 1 0 3p e r m a n e n ts e e di m p l a n t[ 1 3 ]a n dt h r e e - d i m e n -
sional conformal external beam radiotherapy(3D-CRT)
[14].
All these techniques, allowing the RT treatment to be
completed within 5 days, as opposed to a 5-7 weeks of
WBI, might increase the use of BCS, by helping to over-
come the “logistical barriers” (age/age morbidity, time,
travel difficulties, absence from family/job, costs, waiting
list delays for RT or chemotherapy, etc.) and providing
more women with this option.
Another advantage of APBI could be a decreased dose
to lungs and heart. Several data have emerged about a
potential correlation between WBI and the risk of cardi-
ovascular and pulmonary toxicities [15,16], especially in
patients receiving cardio-toxic agents [17,18]. A further
concern is the increased risk of lung cancer in patients
irradiated for breast cancer [16]. Therefore, with a
reduction in irradiated breast volume the heart and
lungs should receive lower doses, reducing the risk of
late toxicity and/or new primary lung cancer.
3D-CRT has several potential advantages, such as the
ability to offer the treatment after full pathologic infor-
mation, decreased operator-dependence, and less finan-
cial expenses. In addition, it is not invasive and is widely
available in all radiotherapy departments equipped with
standard modern facilities (multileaf collimators, CT
simulation, dedicated couch, treatment planning
system).
Although some studies are currently ongoing, no data
on the superiority of a selected technique and/or fractio-
nation schedule has yet been reported. However, caution
should be taken on late toxicity of PBI using larger
dose/fraction. Therefore, cosmetic outcome and toxicity
need to be more fully investigated.
A PBI approach based on Single Shot 3D-CRT PBI
(SSPBI) with patients in prone position has been
reported by our Institute to be feasible and able to spare
heart and lungs [19]. However, the reported follow-up
was too short to draw any conclusion regarding radia-
tion induced late toxicity. In this paper we report the
acute and late toxicity, including fibrosis and cosmetic
outcome, on a larger cohort of patients who underwent
SSPBI in prone position, with the aim to describe the
dose effect relationship based on the updated radiobio-
logical parameters.
Methods
Patients
Eligibility criteria were: Age ≥48 years with a life expec-
tancy of at least 5 years, post-menopausal status, histo-
logically proven, non lobular, adenocarcinoma of the
breast, primary tumor ≤ 3 cm, negative surgical margins
(≥ 2 mm), negative sentinel nodes or <4 positive axillary
nodes, no extra-capsular extension, no previous radio-
therapy. Patients with multicentric disease, extended
intraductal component (EIC>25%), Paget’s disease of the
nipple, lobular adenocarcinoma, distant metastases, were
not included in this study. The protocol has been
approved by the local Ethics and Scientific Committee.
All patients were informed and provided a written
informed consent.
Patients underwent physical examination and photo-
graphs at baseline and once a week for one month after
SSPBI, every month for the first 3 months and every six
months afterwards. Systematic photographs (one frontal
and two profile) were taken under the same patient
position.
Acute/late toxicity was assessed using the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE),vers.3.0[20]. Fat necrosis was
scored according to the system proposed by Lövely et
al.[21].Toxicity was defined as acute/late if it occurred
before/after the 6-month post-RT.
Based on modified Harvard criteria[22], cosmesis was
defined on a four-point scale (excellent/good/fair/poor),
by a physician not involved in the study, comparing pre-
RT baseline breast photographs with those taken at the
last follow-up. An “Excellent” score indicated that the
treated breast was essentially the same (minimal or no
difference in size/shape). A “Good” score indicated
minimal but identifiable RT-related effects (slight differ-
ence in size/shape). A “Fair” score indicated significant
readily observable effects (moderate deformity with
n o t a b l ed i f f e r e n c e si nt h es i z e / s h a p e ) .A“Poor” score
indicated severe sequelae (marked changes in the
appearance involving more than one quarter of the
breast).
The local, regional and distant relapse was assessed
during follow-up based on clinical and radiological
examination. In particular mammography and breast US
examinations were done at 6 and 12 months after SSPBI
and then once a year.
Radiotherapy treatment
Patients underwent the CT simulation and treatment in
prone position on a specifically designed home-made
couch with a circular aperture, allowing the involved
breast to hang from the chest wall and to receive radia-
tion from multiple fields with the gantry in the horizon-
tal position. Adequate immobilization prevents any
breast movement related to breathing, enabling precise
target volume (PTV) definition and treatment. Technical
and physical details of the procedure have been fully
described in a previously published paper [19]. Briefly,
the patient is in prone position on a particular home-
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CT (Figure 1.a) and treatment couch (Figure 1.b). This
device basically consists of a table top with a square
opening, with a side of 30 cm, at the center of the prox-
imal side where different square frames can be placed.
The frames (Figure 1.c), through which the breast hangs
down, have a circular opening of different diameters (11
to 19 cm). The thoracic region around the patient’s
breast can be fastened to the frame by means of thin
circular plastic pads glued to the skin by their adhesive
area (Figure 1.d). Polymethyl methacrilate (PMMA)
bolts at the center of the other side, can be screwed to
the numbered holes drilled along the opening rim, thus
ensuring the breast repositioning and steadiness. A simi-
lar approach was already tested by Formenti and co-
workers [14].
The tumor bed was identified by the metallic clips
positioned at the time of surgery. In all other patients
the tumor bed was defined according to tumor location
in preoperative mammographic images and by the dif-
ference in density on CT slices, between the mammary
and scar tissue. The tumor bed consisted of the scar tis-
sue formed after the mammary gland flaps were sutured
leaving virtually no gap between them. The CTV was
finally contoured on every 3 mm CT slices by adding
1.5-2 cm of breast tissue to the tumor bed.
T h eP T Vw a so b t a i n e db y3m mu n i f o r me x p a n s i o n
around the CTV and was limited by the skin and the
chest wall. The organs at risk (OARs) included the skin,
the remaining ipsilateral/contra-lateral breast, ipsilateral
lung and heart. The contours of a representative patient
are reported in Figure 2.a.
3D-CRT treatment plans were developed with the
Eclipse v.6.5 (Varian Medical System, Palo Alto, CA) by
using five fixed non coplanar beams of 6 MV photons
covering 220 degrees (Figure 2.b). Dynamic wedges were
Figure 1 Positioning device and patient preparation. Positioning device hooked to the a) CT simulator and b) Varian treatment couch with
PMMA frames with a 15 cm diameter circular opening placed inside the table top, c) PMMA frames with different diameters and positions, d)
Patient preparation: the contra-lateral breast was bandaged, the pads are glued to the skin by their adhesive area, when the patient lies on the
table the plastic bolts are inserted inside the corresponding holes and the breast is fixed to the table by nuts.
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along the thoracic wall to nipple direction and for the
non symmetrical fields arrangement. Dose distribution
in a representative patient in a) trasversal, b) coronal,
c) sagittal plane is reported in Figure 3. The occur-
rence of breast motion due to respiration during irra-
diation was monitored by using electronic portal
images by means of Portal Vision aS500 image detec-
tor (Varian Medical System) set in cine modality, veri-
fying the position of a lead marker aligned to the exit
site of the beam isocenter, before and immediately
after the treatment delivery on the image sequences
( F i g u r e4 ) .Ad o s eo f1 8 G y( i nt h ef i r s t4p a t i e n t s )o r
21Gy (in the remaining 60 patients), normalized to the
PTV mean dose, was prescribed in a single session.
The treatment time was 5-7 minutes, by using a dose-
rate of 600 MU/min.
Additional recommendations included: dose ≥ 50% of
the prescribed dose (PD) to ≤50% of the ipsilateral, i.e.
normal breast tissue (INBV = WBV-PTV) (V50%
PD≤50%), and doses as low as possible to the ipsilateral
breast skin. The maximum and mean dose to WB,
INBV and skin were calculated, as well as, the PTV/WB
i.e. the ratio between the PTV and the WB volume. The
recorded dosimetric characteristics for WB also include
VXGy(%/cc), that represents the percentage/absolute
volumes receiving more than XGy.
Radiobiological consideration
The dose of 21Gy in a single fraction was established on
the basis of the biologically effective dose (BED) given
by: BED=(nd)x(1+d/a/b) [23] where n is the number of
fractions, d is the dose/fraction and a/b indicates the
response to the dose fractionation. In fact, the standard
Figure 2 Contours and clips on CT slices. a) CT slice with clips, CTV, PTV and OARs, including INBV = ipsilateral normal breast volume, IBSV =
ipsilateral breast skin volume. b) fields arrangement.
Figure 3 Dose distribution. Dose distribution in a representative patient in a) trasversal, b) coronal, c) sagittal plane. PTV outlined in black.
Some surgical clips are visible.
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w e e k s-5 0G yt ot h ee n t i r eb r e a s tw i t hp h o t o nb e a m s
plus a boost of 10 Gy to the tumor bed with electron
beams has a corresponding BED of 72 Gy (using a/b =
10 Gy), corresponding to a biologically equivalent single
dose of 22.3 Gy. Therefore, a single dose of 21 Gy was
considered reasonable to treat the tumor, in agreement
with Veronesi et al. [24], who reported different dose
levels tested from 10 to 21 Gy without significant side-
effects after a median follow-up of 36 months.
Study design and Statistical analysis
This study was designed as a prospective “single-arm
study” having an unsatisfactory (poor or fair) cosmetic
outcome not superior to the conventional WBI (50 Gy
+boost), maintaining an equivalent local control. The
sample size (100 patients) was calculated to estimate the
unsatisfactory cosmesis rate or ≥Grade 2 (G2) toxicity
(expected to be about 10%) with a standard error of 3%.
Decision rules were drawn up to stop the trial early if
≥15% of patients showed an unsatisfactory cosmesis or
≥G2 toxicity at any point.
For all endpoints, patients were censored at the time
of the specific event. Actuarial curves for late toxicity
were calculated by the Kaplan-Meier product-limit
method and compared by the log-rank test.
Univariate and multivariate analyses (UVA/MVA)
were used to determine covariates associated with an
increase in ≥G2 fibrosis or fat necrosis rate. Clinical and
dosimetric factors tested by univariate analysis included
chemotherapy (yes/no), hormone-therapy (yes/no),
upper/lower/supero-external quadrant (yes/no), post-
operative complications (yes/no), PTV/WB>10% (yes/
no), V18 Gy>20% (yes/no), V21 Gy>66 cc (yes/no),
PTV>97 cc (yes/no), WB mean dose>9 Gy (yes/no), skin
mean dose>5 Gy (yes/no). To compare groups the med-
ian values of dosimetric/volumetric data was taken as
cut-off. While in the MVA, dosimetric and volumetric
factors were considered as continuous variables.
Odds ratios and 95% confidence interval (CI) were cal-
culated for cosmesis/fibrosis. T-tests for continuous
variables were performed. Differences between groups
were also evaluated by the Mann-Whitney test. All
times were calculated from the day of radiotherapy.
Results
The study was stopped prematurely before reaching the
planned sample size of 100 patients, due to the unex-
pected unsatisfactory cosmesis rate or ≥G2 toxicity.
From March 2006 to January 2008, 64 patients, median
age 66 years who underwent BCS and sentinel node
biopsy and/or axillary dissection for early breast adeno-
carcinoma were treated in prone position with an adju-
vant SSPBI schedule to the index area. Sixteen patients
(25%) received adjuvant, non-concomitant, chemother-
apy, consisting of CMF (Cyclophosphamide 600 mg/
m2), Methotrexate (40 mg/m2,5-FU 600 mg/m2;d1 and
d8;q4 weeks × 6) in 5 patients, or FEC (5-FU 600 mg/
m2,Epirubicin 60 mg/m2), Cyclophosphamide (600 mg/
m2;d1;q3 weeks × 6) in 5 patients, or EC (Epirubicin 60
Figure 4 Treatment setup verification by portal imaging. Treatment setup verification by portal imaging. a) Image acquired with gantry at
90 degrees. b) portal image matched with the DRR image. The breast correct position is verified by lead marker and breast profile alignment.
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in 1 patient, or EC followed by Docetaxel (100 mg/m2;
d1;q3;weeks × 4) in 5 patients. Adjuvant chemotherapy
was completed 3/4 weeks before SSPBI except in one
patient (who received chemotherapy one-week after).
Adjuvant hormone-therapy, with Tamoxifen (6 pts.) or
Anastrozole (44 pts.) or Letrozole (8 pts.), if indicated,
was given simultaneously with SSPBI. Patient, tumor
and treatment related characteristics are listed in Table
1. The median follow-up was 37 months. The main
dosimetric and volumetric characteristics are reported in
Table 2.
Acute toxicity
Table 3 shows the acute toxicity observed in our cohort.
Nineteen (30%) patients complained of a G1 acute pain,
which developed only at the end of treatment, likely due
to the immobilization position discomfort, and disap-
peared within 1-2 days. No G2 or more acute pain toxi-
city was detected.
G1, G2 and G3 acute erythema was observed in 11
(17%), 9 (14%) and 1 (2%) patients, respectively. A sta-
tistically significant correlation was found between the
≥G1 erythema and the skin mean dose (p = 0.008),
WB mean dose (p = 0.008), V18 Gy (p = 0.009), PTV
(p = 0.010) and PTV/WB ratio (p = 0.041). No correla-
tion was found between acute toxicity and
chemotherapy.
Late toxicity
Table 3 shows the late toxicity observed and the cos-
metic outcome. The main results of UVA are reported
in Table 4. G1 hyperpigmentation was observed in 10
patients (16%) with no correlation with dosimetric/volu-
metric data. No patient developed G2 or more
hyperpigmentation.
G1 and G2 telangectasia (Table 3) was observed in 16
(24.5%) and 1 (2%) patients, respectively. Telangectasia
was found to be correlated with hormonal therapy (p =
0.0178), V18Gy >20% (p = 0.032), V21Gy>8% (p = 0.0352),
the PTV volume larger than 97 cc (p = 0.0406) and pre-
vious acute erythema (p = 0.0132).
From the 64 patients, 29 and 1 patients complained of
a G1 and G2 late pain, respectively, the latter likely
related to G3 fat necrosis (see later). Late pain (Table 3)
was more frequently reported after the irradiation of the
lower than the upper quadrant (83% vs.43%, respec-
tively, p = 0.0446).
Subcutaneous fibrosis was detected in 51(80%)
patients. Fibrosis was mild (G1) in 23 (36%), moderate
(G2) in 20 (31%) and severe (G3) in 8 (13%) patients.
G1,G2 and G3 fat necrosis were observed in 1 (1.5%), 1
(1.5%) and 1 (1.5%) patient, respectively. Figure 5 shows
the radiological imaging of G3 fat necrosis.
Table 1 Main patient characteristics
Age (years) median (range) 66.5 (51-87)
Histology Ductal/others 55/11
Grading (G)
1 13
2 43
3 8
Chemotherapy
yes/no 16/48
Hormonotherapy yes/no 58/6
TAM 6
A4 4
L8
Estrogen receptor
RE+ 58
RE- 6
Progesteron receptor
RP+ 51
RP- 13
tumor side right/left 26/38
tumor diameter (mm) median (range) 12(2-30)
Quadrant
Upper 58
Lower 6
Tumor stage
Tis 1
T1 53
T2 10
Nodal stage N0/N1 60/4
Follow-up (months) median (25
th -7 5
th) 37(31 -39)
Abbreviations:TAM = tamoxifen; A = anastrozole; L = letrozole
Table 2 The main dosimetric and volumetric data
observed in our patients’ group.
Parameter Median Min Max
CTV volume (cc) 79 15 240
PTV volume (cc) 96 17 290
PTV minimum dose (cGy) 1804 829 1988
PTV mean dose (cGy) 2112 1797 2181
PTV maximum dose (cGy) 2185 1870 2247
Whole breast volume (cc) 892 230 2608
Whole breast mean dose (cGy) 971 436 1411
INBV (cc) 743 205 2441
INBV mean dose (cGy) 740 100 1153
Skin volume (cc) 165 64 385
Skin mean dose (cGy) 544 246 845
V2.1 Gy (%) 84 41 99
V18.0 Gy (%) 20 5 41
V21.0 Gy (%) 9 0 28
V21.0 Gy (cc) 67 0 263
PTV/WB 12% 3% 26%
Abbreviations: WB = Whole breast; INBV = WB volume -PTV; PTV/WB = ratio
between PTV and WB volume; VXGy(%) or VXGy(cc), that represent the percent of
the breast volumes or the volume (cc) receiving more than × Gy, respectively.
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necrosis correlated with the V18Gy>20% (p = 0.0258) or
V21Gy>66cc (p = 0.00043), the WB mean dose>9Gy (p =
0.0284) and the PTV>97cc (p = 0.0133), while ≥G2
fibrosis/fat necrosis(corresponding to a marked increase
of density and firmness on palpation with/without
retraction/fixation) correlated to the V21Gy>66cc (p =
0.0033).
The ≥G1 fibrosis/fat necrosis odds risk was 4.2 (95%
CI:1.1-15.5) when PTV/WB>10%; 15 (95%CI:1.8-125)
when V18Gy>20% and 5.7 (95%CI:1.4-24) when the WB
mean dose was >9Gy. The odds risk of ≥G2 fibrosis/fat
necrosis was 3.2 (95%CI:1.1-8.8) when V21Gy was over
66cc.
Based on MVA, the ≥G1 or ≥G2 fibrosis/fat necrosis
toxicity was statistically (p = 0.02) or as trend (p = 0.09)
correlated to the breast volume receiving more than
21Gy. In particular the higher the volume of breast
exposed to this threshold dose, the greater the risk of
developing a ≥G1 or ≥G2 fibrosis/fat necrosis reaction,
with an increment of risk of 0.006 per each cc of breast.
The cosmetic outcome was scored in all patients.
Good/excellent cosmesis was observed in 38 patients
(59%), fair and poor cosmesis in 23 (36%) and 3 (5%)
patients, respectively (Table 3). Figure 6 shows a patient
with excellent cosmesis along with the only 3 patients
with poor cosmesis.
No correlation was found between cosmesis (good/
excellent vs.poor/fair) and dosimetric/volumetric data
with the exception of WB mean dose >9Gy (p = 0.030).
Moreover, a correlation between cosmesis and ≥G2 or
G3 fibrosis (P < 0.0012 and 0.0003, respectively) was
found. The odds risk analysis confirmed no correlation
between cosmesis and clinical/dosimetric or geometric
parameters. No correlation was found between late toxi-
city and chemotherapy data.
Recurrence
One patient, who met the ASTRO’s “cautionary” criteria
for APBI, underwent mastectomy for suspected recur-
rence, histologically confirmed. Of relevance, this patient
was free from any grade of subcutaneous fibrosis.
Discussion
In recent years a number of phase I-II trials have been
published with the aim of exploring the feasibility of
hypo-fractionation regimens, delivering total doses
between 10 to 38.5Gy, assumed to be equivalent to 45-
50Gy at 1.8-/2Gy/fraction using an a/b of 10 Gy [24],
as a possible alternative to conventional WBI schedules.
Whereas, most initial experiences with APBI using
brachytherapy[9,11-13,25-29] have led to optimal results
in terms of local control and toxicity, data regarding the
acute and late toxicity with external beam PBI are sparse
and rather conflicting. By delivering a dose of 38.5Gy in
Table 3 Acute and late toxicity observed in our cohort.
Toxicity G0 G1 G2 G3
Acute pain 70% 30% 0% 0%
Acute erythema 67% 17% 14% 2%
Hyper-pigmentation 84% 16% 0% 0%
Teleangectasia 73% 25% 2% 0%
Late pain 53% 45% 2% 0%
Subcutaneous fibrosis or fat
necrosis
19% 36% 31% 14%
(cosmetic outcome) (excellent) (good) (fair) (poor)
breast appearance 20% 39% 36% 5%
Table 4 Results based on univariate analysis
Parameters p-value
Erythema (≥G1vs. G0) against skin mean dose 0.008
Erythema (≥G1vs. G0) against WB mean dose 0.008
Erythema (≥G1vs. G0) against V18 Gy 0.009
Erythema (≥G1vs. G0) against PTV 0.010
Erythema (≥G1vs. G0) against PTV/WB 0.041
Telangectasia (≥G1vs. G0) against hormonal therapy 0.0178
Telangectasia (≥G1vs. G0) against V18Gy >20% 0.032
Telangectasia (≥G1vs. G0) against V21Gy>8% 0.0352
Telangectasia (≥G1vs. G0) against PTV > 97 cc 0.0406
Telangectasia (≥G1vs. G0) against previous acute erythema 0.0132
Late pain (≥G1vs. G0) against the upper quadrant 0.0446
Fibrosis/fat necrosis (≥G1vs. G0) against V18Gy>20% 0.0258
Fibrosis/fat necrosis (≥G1vs. G0) against V21Gy>66cc 0.00043
Fibrosis/fat necrosis (≥G1vs. G0) against WB mean dose>9Gy 0.0284
Fibrosis/fat necrosis (≥G1vs. G0) against PTV>97cc 0.0133
Fibrosis/fat necrosis (≥G2vs. G0-G1) against V21Gy>66cc 0.0033
Cosmesis (good/excellent vs.poor/fair) and WB mean dose
>9Gy
0.030
Cosmesis (good/excellent vs.poor/fair) and ≥G2 fibrosis <0.0012
Cosmesis (good/excellent vs.poor/fair) and G3 fibrosis 0.0003
Figure 5 G3 fat necrosis. Mammographic image of G3 fat necrosis
observed in 1 patient.
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papers showed no or very few local recurrence with
excellent/good cosmetic results in 88-90% of patients
[30-32]; while others showed a poor/fair cosmesis and/
or moderate/severe fibrosis in 25-32% of patients with
no conclusion on tolerance/efficacy of PBI versus
conventional radiotherapy [33,34]. In the latter two
papers the poor cosmetic/toxicity outcomes were related
to the large breast volumes treated with relatively high
doses in the postoperative setting.
Two studies with large cohorts showed encouraging
results in terms of cosmesis/toxicity outcomes delivering
Figure 6 Photographs of cosmetic outcome. Photographs a)before and b) after RT of a patient with excellent cosmetic outcome;
photographs c),e),g) before and d),f),h) after RT of three patients with poor cosmetic outcome. The cosmetic outcome was defined according to
modified Harvard criteria (see text).
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has reported with a median follow-up of 36 months
only two patients with severe fibrosis among 1,800
w o m e ne n r o l l e di nt h eE L I O Tt r i a l ,r e c e i v i n gas i n g l e
21Gy intra-operative RT(IORT) using electrons. The 4-
year results of the TARGIT-A trial [35] conducted on
2,232 women from 28 centers in 9 countries showed
that this approach had fewer RT-related side effects
with respect to the conventional WBRT. A recent phase
II study [36] reported 4 patients (9.5%) with G2 subcu-
taneous fibrosis and no ≥G3 side effects among 94
patients, older than 65 years, treated with exclusive PB
IORT at 21Gy fraction, with a median follow up of 30
months. All these studies confirm the feasibility of
IORT for treating early-stage breast cancer. However,
many centers lack the specialized equipment and exper-
tise required to deliver IORT.
The aim of the present study is to demonstrate the
feasibility of an external beam radio-surgery approach as
a more readily accessible alternative to IORT. In parti-
cular, the cine modality has been used to investigate the
breast movement during treatment. This approach,
based on the verification of the position of lead markers
on the cine images, allows to verify that target move-
ments due to breathing were trivial. To the best of our
knowledge, there are no references in literature report-
ing dose constraints for organs at risk (OARs) to be
used in the breast cancer treatment with single doses of
photons. We used dose constraints reported in our pre-
vious paper [19], in principle based on reducing the
maximum dose to the lowest part of the healthy tissue.
Our study was designed to compare cosmetic results to
WBRT(50Gy+boost), maintaining the same level of
tumor control, assuming a/b = 10Gy, and it is the first
reported experience of post-operative SSPBI by external
photon beam RT as a part of BC treatment. Only one
recent study[37] has tested the feasibility of a single
fraction pre-operative PBI of 15Gy, resulting in a sub-
stantial dose reduction to the ipsilateral breast and a
reasonable skin dose in comparison to their historical
institutional controls treated with post-operative PBI.
However, given the lack of iso-effective dose and the
absence of clinical data no conclusion on outcome was
provided.
Our results are indeed worse (63% of patients with
unsatisfactory cosmetic outcome or ≥G2 late toxicity)
than expected (29%) after conventional WBRT, leading
to the premature closure of the study. Regarding the
cosmetic outcomes, the WB mean dose resulted as a
predictor of poor/fair outcome (p = 0.030). An increase
of >G2 fibrosis(44%) was observed with respect to the
32.4%, reported at 10 years with a conventional fractio-
nation in the European Organization for Research and
Treatment of Cancer(EORTC) trial when the boost was
treated[38]. In addition, our toxicity rate is higher than
Chen et al.[32] reporting a moderate/severe fibrosis rate
after external beam APBI of 25% after similar median
follow-up, while it is in contrast with minimal local side
effects reported in ELIOT/TARGIT studies. When
investigating the late toxicity of APBI treatments it is
critical to consider the differences in follow-up times:
estimates suggest that 90% of the ultimate incidence
(peak hazard) of fibrosis is expressed by approximately 4
years post-RT, depending on the grade of reaction and
the intensity of the schedule[39]. Thus, our results do
have the maturity of follow-up to draw reasonable con-
clusions about toxicity/cosmetic outcome.
Although adjuvant cytotoxic chemotherapy[40] has
long been recognized as a risk factor for radiation-
induced fibrosis after postoperative RT for breast cancer
[41], we do not find any correlation with acute/late
toxicity.
Understanding the impact of volume effect is impor-
tant when considering fibrosis: larger volumes in our
cohort seem to be predictive of ≥G1 or ≥G2 toxicity (P
< 0.0001 and p = 0.0033,UVA). This correlation is con-
firmed for ≥G1 toxicity (p = 0.02, MVA) and becomes a
trend for ≥G2 toxicity (p = 0.09,MVA).
Of note, the target volumes in our group (mean:108
cc, range:17-290 cc) were lower than those reported in
other APBI series (the PTV evaluable mean:185- 296 cc,
range:67-950 cc) this is probably due to the different
surgical technique that involves the suture of the surgi-
cal breach without the formation of a lumpectomy cav-
ity. Therefore, the use of a single dose is expected to be
more toxic on normal tissues as well as effective on
tumors, while lower volumes decrease the incidence of
severe fibrosis(13%). Thus, the volume effect could
explain the very limited moderate-severe fibrosis/fat
necrosis, in 2/4.2% of patients, respectively, reported by
Veronesi et al.[24]. In fact, with an applicator diameter
of 4-6 cm and a dose of 21Gy prescribed at the level of
90% of the isodose, the expected V18Gy should range
from 26 to 71 cc using a Novac (energies:7-9 MeV,
a p p l i c a t o r s : 4 0 - 6 0m m )a n df r o m3 4t o8 5c cu s i n ga
Liac(energies:6-10 MeV, applicators:40-60 mm). The
same observation may be suitable for TARGIT-A[35],
where the Intra-beam device provides a point source of
low energy X-rays(50kV maximum) at the tip of a
3.2mm diameter tube placed at the centre of a spherical
tumor bed applicator. Thus, the volume effect should
decrease the rate of toxic effects after a single high dose.
In fact, in the TARGIT trial, doses of about 20Gy have
been delivered using photon beam in a single fraction
[35].
Another crucial issue is that the use of larger dose/
fraction in APBI protocols presents specific radiobiolo-
gic concerns because of a possible reduction in
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doses to maintain the same level of tumor control. The
biological effects of a single dose under these circum-
stances might be different from those predicted from
the LQ model. In particular, tumor hypoxic cells cannot
reoxygenate, as occurs during fractionated RT, remain-
ing radioresistant. In addition, some cells can be found
in the “Sp h a s e ” of the cell cycle (i.e. to be more radio-
resistant) and exhibit a greater level of survival com-
pared to cells in “G2 phase” or mitosis [42]. Thus, a
single fraction should require higher doses than those
calculated with the LQ model.
Veronesi et al. [24] reported an actual local recurrence
of 2.3% and an ipsilateral breast cancer of 1.2%.
Whereas, in our series with a similar median follow-up
the local recurrence was 1.6% (1/64) with no ipsilateral
breast cancer, showing that local control rates compare
favorably to other series after intra-operative delivery
[24,36,37].
Regarding the BED using an a/b ratio of 10Gy our
treatment schedule of 21Gy in single fraction is consid-
ered to be equivalent to a standard WBI of 50Gy+boost,
while the other regimens using 3D-CRT or brachyther-
apy were equivalent to 50Gy.This leads to the following
consideration; emerging data from several prospective
randomized clinical trials [43-45] of hypofractionated
WBI have recently estimated an a/b values of 4.6Gy for
TCP and 3.4Gy for late changes in breast appearance (a
surrogate of late toxicity). Adopting a low a/b ratio,
BED values associated with our schedule were 116.9Gy
and 157.0Gy for a/b ratios of 4.6Gy and 3.4Gy, respec-
tively. These BEDs might have led to unexpected out-
comes, worsening cosmesis/fibrosis, which could also be
due to the larger volumes in our cohort (based on the
additional margins to CTV used to reduce the rate of
geographical missing), respect to IORT treatments with
electron beams.
Considering the wide variability in treatment-related
toxicity observed in our cohort, only in part explained
by dosimetric factors, we aim at a closer scenario in
which new factors, such as polymorphisms combined
with dose parameters could better explain the different
clinical radio-susceptibility [46].
Conclusions
SSPBI in breast cancer patients after conservative sur-
gery is feasible, however, based on our results and on
the conflicting outcome reported in other PBI studies,
we urge caution when applying this approach in the
clinical practice. The single dose of 21Gy equivalent to a
standard dose plus boost adopted in this prospective
trial significantly increased the treatment-related toxicity
in our cohort. However, this should not discourage the
adoption of novel SSPBI approaches with lower
e q u i v a l e n td o s e sa st h ea d v a ntages still outweigh the
drawbacks.
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